• Bulletin 181 - Barrier products now available to all PrescQIPP users

    Bulletin 181 - Barrier products is now available to all PrescQIPP users, with some additional resources still only available for subscribers.

    This bulletin reviews the place in therapy of barrier preparations and includes resources which focus on using products appropriately and avoiding waste.  A pathway and formulary product selection guidance are available as supporting tools. 

    Info_bulletin_SQ_preopt.png  Barrier products

    Tags:
  • Bulletin 176 - Polypharmacy and deprescribing - A practical guide to deprescribing now available to all PrescQIPP users

    Bulletin 176 - Polypharmacy and deprescribing - A practical guide to deprescribing is now available to all PrescQIPP users, with some additional resources still only available for subscribers.

    This bulletin and supporting resources provide practical guidance on deprescribing. Support tools include a medication review template and deprescribing algorithms which are both generic and drug class specific. these tools can be used to guide the process of deprescribing in patients.

    Info_bulletin_SQ_preopt.png   Polypharmacy - Practical guide to deprescribing

    Tags:
  • Bulletin 173 - Care homes - Implementation of NICE guidelines now available to all PrescQIPP users

    Bulletin 173 - Care homes - Implementation of NICE guidelines is now available to all PrescQIPP users.

    This bulletin discusses the implementation of NICE guidance relevant to medicines optimisation in care homes. A summary of relevant NICE guidance and suggestions to support implementation are offered for each of the relevant NICE guidance. Links to supporting resources are also available. This resource is designed to be shared with care home staff.

    Info_bulletin_SQ.png  Care homes - Implementation of NICE guidelines

    Tags:
  • Bulletin 168 - British Association of Dermatologists revised guidelines (SPOT-List) now available to all PrescQIPP users

    Bulletin 168 - British Association of Dermatologists revised guidelines (SPOT-List) is now available to all PrescQIPP users.

    This bulletin reviews the prescribing of dermatology specials to try and ensure that any prescribing of dermatology specials is appropriate and in line with the British Association of dermatologists guidelines. A data pack is available to subscribers to support local review. 

    Info_bulletin_SQ.png   Dermatology specials (SPOT-List)

    Tags:
  • Bulletin 164 - Controlled drugs monitoring now available to all PrescQIPP users

    Bulletin 164 - Controlled drugs monitoring bulletin is now available to all PrescQIPP users, with some additional resources still only available for subscribers.

    The controlled drugs bulletin and resources have been written to support CCG teams that have a role in supporting the regional NHS England Controlled Drugs Accountable Officer (CDAO). 

    An audit tool, standard operating procedure template and letters are available to adapt and use as supporting resources. All our controlled drugs resources will also be available on the controlled drugs webkit which includes the CD monitoring datasets. 

    Info_bulletin_SQ_preopt.png   Controlled drugs monitoring

    Tags:
  • Bulletin 145 - Nutrition: Sip feed guideline update now available to all PrescQIPP users

    Bulletin 145 - Nutrition: Sip feed guideline update is now available to all PrescQIPP users.

    These guidelines update the previous ONS guidelines and set out the steps for prescribing ONS and provide useful advice on monitoring progress as well as for prescribing in malnutrition associated with special conditions such as palliative care or drug misuse. Advice on self care, reducing inappropriate prescribing and waste is also included. 

    Info_bulletin_SQ.png   ONS guidelines

    Tags:
  • Bulletin 175 - Hypnotics update now available to all PrescQIPP users

    Bulletin 175 - Hypnotics update is now available to all PrescQIPP users.

    Due to concerns over hypnotic dependence, hypnotic prescribing has been subject to scrutiny and review for a number of years. In this bulletin, we offer advice on managing new patients with insomnia, recommend cost-effective prescribing choices,  and encourage you to review chronic hypnotic users with a view to helping them withdraw from treatment. We recognise that this is not an easy task, but we have developed and included links to some useful implementation tools to assist you.

    Info_bulletin_SQ.png  Hypnotics

    Tags:
  • Bulletin 43 - Inhaled therapy in COPD now available to all PrescQIPP users

    Bulletin 43: Inhaled Therapy in COPD is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    This bulletin considers the cost effective options for inhaled therapy for patients suffering with COPD, looking at the longer term costs of treatment. Along with audit reports, patient information materials, SystmOne searches and data collection tools, this bulletin offers a longer term view for CCGs, in line with the Medicines Optimisation agenda.

     Inhaled Therapy in COPD

    Tags:
  • Bulletin 44 - Gliclazide now available to all PrescQIPP users

    Bulletin 44: Gliclazide is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    This bulletin focuses on gliclazide modified release and provides the rationale for new patients to be commenced on gliclazide standard release, and for current patients to be considered for a switch to either metformin or gliclazide (or both depending on where the patient is on the treatment pathway). It also reviews the use of metformin modified release and offers advice on switching appropriate patients to standard release metformin.

     Gliclazide

    Tags:
  • Bulletin 46 - Blood glucose testing strips now available to all PrescQIPP users

    Bulletin 46: Blood glucose testing strips is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    The bulletin and accompanying documents focus on appropriate prescribing of blood glucose testing strips for people with type 2 diabetes mellitus and also improving prescribing efficiencies in this area. It includes recent prescribing figures and potential savings from switching patients on to cost-effective blood glucose meters and testing strips. An implementation guide for blood glucose meter selection is also available.

     Blood Glucose Testing Strips

    Tags:
  • Bulletin 47 - Omega-3 fatty acids (DROP-List) now available to all PrescQIPP users

    Bulletin 47: Omega-3 fatty acids (DROP-List) is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    This is one of a number of bulletins providing further information on medicines contained in the DROP-List
    (DRugs Of low Priority). This bulletin focuses on omega-3 fatty acids and provides the rationale for therapy to be stopped or for patients to be switched to alternative agents and for new patients not to be started on omega-3 fatty acids. 
     
    Tags:
  • Bulletin 48 - Liquid formulation requirements in bariatric surgery patients now available to all PrescQIPP users

    Bulletin 48: Liquid formulation requirements in bariatric surgery patients now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    The number of weight-loss bariatric procedures has been on the increase, especially since the publication of NICE guidelines on obesity in which bariatric surgery was recommended as a treatment option for some patients. Following bariatric surgery, patients are restricted to a liquid diet and their medications are usually changed from solid dosage forms to unlicensed liquid formulations. This switch may not be necessary or may continue for longer than the clinical need and can have significant implications for the drug budget. This bulletin provides information for prescribers on the appropriate prescribing of liquid formulations for patients that have undergone bariatric surgery.
     
     

     

    Tags:
  • Bulletin 51: Lidocaine plasters (DROP-List) now available to all PrescQIPP users

    Bulletin 51: Lidocaine plasters, is now available to all users of the PrescQIPP site. As most of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    This bulletin looks at lidocaine plasters and provides the rationale for not initiating lidocaine plasters in new patients, and for current patients to be considered for discontinuation of their prescription for lidocaine plasters. 

      Lidocaine plasters

    Tags:
  • Bulletin 52: Oxycodone MR now available to all PrescQIPP users

    Bulletin 52: Oxycodone MR, is now available to all users of the PrescQIPP site. As most of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    This bulletin reviews the place in therapy of oxycodone MR and offers guidance and support material for organisations considering reviewing oxycodone MR prescribing as a QIPP project. The accompanying briefing summarises the key points for your team and local clinicians, whilst the data pack and implementation tools provide you with resources to support and carry out a review in your area.

     Oxycodone MR

    Tags:
  • Bulletin 50 - Pregabalin in neuropathic pain now available to all PrescQIPP users

    Bulletin 50: Pregabalin in neuropathic pain is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    Across the PrescQIPP membership (approximately 16.4 million patients) over £60 million is spent annually on pregabalin (ePACT May 2013). This bulletin reviews the place in therapy of neuropathic pain treatments and offers guidance and support material for organisations considering reviewing pregabalin and gabapentin prescribing as a QIPP project. It supports the implementation of NICE Clinical Guideline 173. 

     Pregabalin in neuropathic pain

    Tags:
  • Bulletin 55 Amorolfine 5% nail lacquer (DROP-List) now available to all PrescQIPP users

    Amorolfine 5% nail lacquer is now available to all users of the PrescQIPP site. As some of you will be aware, since changing to a subscription based model, our bulletins and toolkits are only available to paid subscibers in the first instance for 4 months. This period has now passed for this bulletin and we are pleased to make you all aware that it can now be accessed by anyone via the site.

    This bulletin from the PrescQIPP DROP-List and focuses on topical antifungal nail treatment, i.e. amorolfine 5% nail lacquer (Loceryl®, Curanail®, Omicur®), tioconazole 28% cutaneous solution (Trosyl®) and salicylic acid, tannic acid and boric acid paint (Phytex®) which are low priority treatments. Self-care may be appropriate for the majority of asymptomatic patients with fungal infection of the nails. If treatment is deemed necessary, a systemic antifungal is more effective than topical therapy.

     Amorolfine 5% nail lacquer

    Tags:
  • Bulletin 57 Eflornithine (DROP-List) now available to all PrescQIPP users

    Eflornithine is now available to all users of the PrescQIPP site.
     
    This bulletin focuses on eflornithine cream which is a low priority treatment considered as a cosmetic treatment for hirsutism in women. It provides the rationale for self-funded hair removal methods as the primary treatment option for women with hirsutism. It is no.19 on the PrescQIPP DROP-List and is the second PrescQIPP publication to contain a data pack and the new style briefing alongside the bulletin and implementation tools.
    Tags:
  • Bulletin 62: Tramacet (DROP-List) now available to all PrescQIPP users

    Tramacet (DROP-List) is now available to all users of the PrescQIPP site.

    This bulletin  focuses on Tramacet® (paracetamol 325mg/tramadol 37.5mg) and provides the rationale for new patients to be initiated on paracetamol or paracetamol with codeine. Current patients should be considered for a switch to paracetamol alone or paracetamol with codeine. Information on the adverse effects of Tramacet®, options for dose conversion in support of the switch and potential switch savings are provided.

     Tramacet

    Tags:
  • Bulletin 61: Montelukast now available to all PrescQIPP users

    Montelukast is now available to all PrescQIPP users.

    Annual spend across the PrescQIPP for the leukotriene receptor antagonists montelukast and zafirlukast is almost £3million. This bulletin and supporting materials are aimed at ensuring prescribing of the leukotriene receptor antagonists is generic and also reviewing treatment to assess for continued need in line with the BTS/SIGN Asthma management guideline.
    Tags:
  • Bulletin 53: Silver dressings now available to all PrescQIPP users

    Silver dressings is now available to all PrescQIPP users.
     
    The PrescQIPP silver dressings bulletin focuses on appropriate prescribing of silver dressings and ensuring they are prescribed for a maximum period of two weeks unless assessed by a Tissue Viability nurse. 
     
    Support materials provide summarised advice and audit support for prescribers and nurses requesting prescriptions for silver dressings.
     
     
    Tags: